Atlas Trials

Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Clinical trial NCT05267535 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05267535
Sponsor
Neurim Pharmaceuticals Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Alzheimer's Disease
Start date
2022-05-12
Primary completion
2025-06-01
Enrollment
225

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.